Founder
of Regulon, the inventor of
Lipoplatin and CEO. Teni holds a
B.Sc. degree in Chemistry from the Aristotelian University of Thessaloniki and
a Ph.D. from the Southwestern Medical School in Dallas, Texas in Biochemistry.
As a EMBO postdoctoral fellow, Teni studied at the
Swiss Institute for Experimental Cancer Research in Epalinges sur Lausanne. He
became Assistant Professor of Biochemistry, Head of the Laboratory of
Monoclonal Antibodies at the University of Sherbrooke in Quebec. Teni then
moved to the Linus Pauling Institute in Palo Alto as an Investigator and
Director of the Laboratory of Molecular Carcinogenesis and later at the
Institute of Molecular Medical Sciences (Palo Alto). In 1998 he founded Regulon
based on a patent for the isolation of Regulatory DNA sequences (thus the name
of the Company) and their cloning to express poisonous genes in specific
cancers. He is also the inventor of liposomal encapsulation of cisplatin and
many other drugs. He has over 80 publications. Teni’s passion is to invent new
formulations to improve human health.

Tel: +30 6937 255 067Email: teni@regulon.com

Theodoros Sazaklis MBA

joined Regulon,
Inc., in 2016 as Chief Financial Officer. Before that he had a long career in
Banking and Asset Management. He was a Senior Director at Eurobank Asset
Management, Head of Credit and ABS Trading at Eurobank, Deputy Director of
Fixed Income and Structured Products at Emporiki Investment Bank, Deputy
Investment Manager and Head of Fixed Income at Intertrust Mutual Funds and
Interamerican Insurance and Senior Interest Rate Dealer at Intesa SanPaolo
Bank. In addition, he was a consultant to Regulon Inc. since 2011. He holds an
MBA from Imperial College. He holds a BSc in Computer Science from University
of Athens with Honors (highest GPA score since Department’s inception) and a BA
in Economics from University of Athens.

Tel: +30 695 999 6311Email: theos@regulon.com

Celik Hatipoglu

Senior Vice President, Business Development and Sales, He graduated from the Department of Chemical Engineering of Hacettepe University in Ankara, Turkey. He has worked in the pharmaceutical sector in Turkey as executive manager in various departments like Business Development, Marketing and Sales for nearly 15 years. Çelik has been a member of the Regulon team since 2015 as General Manager of Regulon Turkey and has been serving as Vice President of Business Development and Sales since September 2017.

e-mail: celik.hatipoglu@regulon.com

Stavros Kottaridis, Ph.D.

Member of the BOD, Coordinator of Phase III in Greece.

He
has represented Greece in all major virus strikes at a European level. He is
also a member of the EOF (Greek FDA) committee on biological drugs. As a
director of the Papanikolaou Research Center at Agios Savvas Anticancer
Hospital in Athens for 25 years he collaborated with almost every oncologist in
the country providing expertise assistance with tissue culture and a plethora of
other oncology studies. This role of Stavros was decisive in recruiting
oncology centers in the Phase III studies of Lipoplatin in Greece and
supervising the clinical development of the drug.

E-mail: stavros.kottaridis@regulon.com

Ted Doukas

Senior VP, Business Development based in USA (December 2005). Ted is responsible
for the Corporate office of Regulon in Melville, New
York. A flourishing financier and real estate
developer in the U.S. and abroad, Ted Doukas began his investment career in Long
Island NY, where acquiring first class office, retail and residential
properties throughout affluent Nassau and Suffolk Counties, he became one of
the largest individual property in the area’s history. As volatility in the
real estate market spread, Doukas’ abilities to develop and turnaround complex
projects has led him to extensively expand his work into the beleaguered
markets. Born in Greece, Doukas studied Medicine for two years at the
University of Pisa in Italy before coming to the U.S. where he was educated in
Business at New York Institute of Technology. Ted is recognized throughout a
myriad of industries for his creative thinking and ability to profitably
implement critical growth-oriented policies.

Christina Karipi M.D

joined Regulon,
Inc (USA) as a Member of Board of
Directors in 2009 and Regulon AE (Greece) as a Medical Officer in 2007. Dr.
Karipi has been responsible for the introduction of Lipoplatin™ at the Sotiria
Pulmonary Disease Hospital in a Phase III study as first line against non-small
cell lung cancer. She holds her Medical degree from the Medical School of
Athens, Greece and her specialization at the 4th Clinic of the Sotiria
Pulmonary Disease Hospital. She has represented Regulon in several business
meetings.

Andrei Lyne

Senior VP, Business Development

He holds a BA from Oxford University
(Baker Scholarship), his MBA from NY University (Director's Fellowship). Andrei
has over 10 years of experience focused on the life sciences sector. Prior to
joining Regulon in 2009 he was an Executive Director in UBS Investment Bank's
Global Healthcare Group, providing corporate development and financial advice
to life science companies globally. At UBS, Andrei was instrumental in several
dozen key client transactions, including six IPOs across the US and Europe
that raised over $1.3 billion for pharmaceutical, biotech and other life
science companies. He also completed over $3 billion of other equity,
equity-linked and debt financing transactions and advised on many
transformational M&A deals.

Tel: +1-917-484-1315Email: andreilyne@gmail.com

Tel: +1-917-484-1315

Constantinos M. Paleos

Born in Chios,
Greece, and obtained his BS in Chemistry from Athens University and his PhD
from Drexel University in Philadelphia. In 1973, after three years with Amoco
Chemicals and Motor Oil (Hellas), he joined the Institute of Physical Chemistry
at NCSR “Demokritos”, where he was elected Director for the periods 1994-1999
and 2001-2007 while currently he is collaborating with this Institute. He was
elected, in the periods 1994-1996 and 2005-2006 Vice President of Board of NCSR
Demokritos. From 2002 he is consultant at Regulon, Inc. In 1991-1992 he was
elected visiting professor at Louis Pasteur University, Strasbourg. His
research activities focus in the area of “Nanomaterials of Supramolecular
Organized Structure” including the synthesis and characterization of liquid
crystals, molecular recognition of liposomal aggregates, modeling cell
processes, preparation and characterization of multifunctional dendritic
polymers, liposomes, drug and gene delivery systems and molecular transporters.
He has published 178 original articles and reviews and his work has received
over 3750 citations, (Source ISI, h-index32).

c.paleos@inn.demokritos.gr

Maria
Stergoudi (Mirella), M.D.,

has graduated from the Medical School of the
Kapodistrian University of Athens, Greece. Following a graduate program, she
has worked with physicians of different expertize in central hospitals of
Athens. She joined Regulon in 2010 as a Medical Officer, working intensively
coordinating clinical studies, communicating with oncologists and initiating
sites worldwide, preparing all necessary study reference documents (protocols,
ICFs, CRFs), as well as reports for local Regulatory Authorities. Mirella acts
as the link between Regulon and physicians, being always on alert to clarify
issues regarding criteria of eligibility, treatment regimens, dose schemes and
modifications and handling possible AEs. She has represented Regulon at the
meetings with EMA and MHRA team in 2012, where dossiers for both Lipoplatin and
Nanoplatin were successfully presented.

Email:
mirella.stergoudi@regulon.com

Faye Lazarioti, M.D

has graduated from the Medical
School of L Aquila, Italy. Specialized in Radiology (Conventional Radiology,
Ultrasonography, Interventional Radiology, CT and MRI) at Evangelismos General
Hospital (Athens) and in Pediatric Radiology at Paidon Pentelis Hospital
(Athens). Faye joined Regulon in 2006 as a Medical
Officer. With over 60 published papers and conference presentations she is
working on the analysis and correlation of imaging findings with the response
to Lipoplatin. In additional she is responsible for managing patient data and
recruiting Oncology Centers in pancreatic, lung, breast and gastric cancer
clinical studies.

E-mail:
faye.lazarioti@regulon.com

Alexandros Pantos, Ph.D.

Chemistry, R&D, Production.

Alex has graduated from the Chemistry Department of the
Kapodistrian University of Athens, Greece and received his M.Sc and Ph.D in
Drug Delivery. During his post-graduated studies he obtained EPEAEK Fellowship
for MSc Studies from Athens University and Fellowship for Excellency Research - GSRT, Greece. He is an expert in
preparation and characterization of drug loaded multifunctional liposomes and
modified dendrimers /hyperbranched polymers for prospected applications as drug
delivery systems. Alex is specialized in several nanoparticle characterization
techniques including thermal analysis (ITC, microDSC). His fields of current interests also include:
studies on the mechanism of adhesion and fusion of multifunctional liposomal
systems resulting in formation of multicompartment systems
which are model of cell interactions. He is author of many presentations
and scientific publications in several high
impact journals in the field of Nanotechnology such as: Langmuir, ChemMedChem,
BBA, Accounts in Chemical Research. He joined Regulon in 2005 as a Senior
Project Chemist and since 2010 is responsible for the Quality Control of
Regulon’s products.

Email: alexandros@regulon.com

Niko
Boulikas

is an expert in Information Technology. He has a critical mind in
presenting our technology and he masters electronic data management including
data on clinical studies and presentation of documents. Niko possesses also web designing skills. His recent achievement is the setting of
a web program for electronic data capture on patients enrolled in Lipoplatin’s
pivotal clinical trials.

E-mail: niko.boulikas@regulon.com

Butenko Alexander Borisovich

Ph.D., Assistant Professor, Head
physician of the rehabilitation center in Moscow, Deputy General Director of Regulon in Russia.

A. Butenko has published 84 scientific works and 2 inventions in the field of clinical biochemistry and oncology. A. Butenko took part directly in the development of the efficacious treatment schemes for solid malignant tumor by using Lipoplatin in
collaboration with the team of Regulon in Athens. A. Butenko has extensive
clinical experience in the treatment of terminally ill cancer patients who were
refused treatment in hospitals because of the advanced stage of their disease.
Such patients include those with stomach, colon, pancreas, nervous system and
lung cancers.

Deniz YÜCE, MD, Ph.D.

in Cancer Epidemiology. Deniz is a Specialist in Preventive
Oncology and Instructor at Department of Preventive Oncology of Hacettepe
University Cancer Institute.

Deniz received his Medical degree from Gazi
University Faculty of Medicine in 2005 and his MSc in Cancer Epidemiology from
Hacettepe University Cancer Institute, Department of Preventive Oncology
in 2011. He then obtained his PhD from the Department of Epidemiology,
Hacettepe University Public Health Institutein 2012. He worked as Physician
in Turkish Red Crescent, Ankara, TURKEY in 2005, as a Physician at the
Emergency Department in Akay Private Hospital, Ankara, TURKEY in 2008, as
Research Assistant in Hacettepe University in 2009, as a Specialist in
Preventive Oncology in 2012 and as Medical Advisor in Regulon Inc. Turkey since 2014. He is responsible for the
treatment of cancer patients in Turkey in a number of different cancers with
Lipoplatin, including breast, lung, ovarian, and others.